The improved functionality of CAR-CCR8-DNR T cells compared to CAR T cells against the HER2 antigen could be demonstrated in vitro and in vivo in human HER2+ tumor models.Conclusions Equipping CAR T cells with CCR8 and DNR emerges as a strategy not only limited to certain antigens, but ...
[6]Elgersma RC,Coumans RG,Huijbregts T,et al.Design,Synthesis,and Evaluation of Linker-Duocarmycin Payloads:Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.Mol Pharm.2015 Jun 1;12(6):1813-35. [7]Xinling Zhang,Andrew ...
[6]Elgersma RC, Coumans RG, Huijbregts T, et al. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. Mol Pharm. 2015 Jun 1;12(6):1813-35. [7]Xinling ...
However, recent studies are promising for the use of CAR-T in HER2 + MBC, particularly when anti-HER2 CAR-T cells are combined with PD-1 antibodies [98]. Clinical trials are currently underway evaluating CAR-T in HER2 + breast cancer with brain or leptomeningeal metastases (NCT...
T-DM1的载药—DM1(微管蛋白抑制剂) T-DM1的载药DM1是美登素类衍生物,但其细胞活性相比美登素有所下降。T-DM1在细胞内经溶酶体降解为赖氨酸残基-连接子-DM1(Lys-SMCC-DM1)复合物形式,因为带有电荷,极性增大,不能有效穿透细胞膜,同样不具有旁观者效应[7,13]。值得一提的是,上述RC48、ARX788、T-DM1的...
ANTI-HER2 PIGGYBAC TRANSPOSON-BASED CAR T CELLS PRODUCTION: COMPARISON OF TWO DIFFERENT SCFV CLONESdoi:10.1016/s1465-3249(22)00895-7E. AragoL. AbdoK. HajduL. SilvaM. BonaminoCytotherapy
Ovarian cancer cells stimulate a cytolytic phenotype of anti-HER2 CAR T cells.Evripidis, LanitisDenarda, DangajIan, S. HagemannDeGang, SongAndrew, BestRaphael, SandaltzopoulosGeorge, CoukosDaniel, J. Powell Jr
We have developed a HER2-CAR-T cells (BP2301) characterized by CAR-T cells comprising abundance of stem cell memory-like T cells (Tscm). In the present study, we evaluated the anti-tumor efficacy of BP2301 using a CCA xenograft model with patient-derived cell transplantation. Methods BP...
T cellsChimeric antigen receptor (CAR) T cell therapy shows promise in treating malignant tumors. However, the use of human epidermal growth factor receptor-2 (HER2) CAR-T cells carries the risk of severe toxicity, including cytokine release syndrome, due to their "on-target...
In pre-clinical studies, CAR-M infiltrate tumors, phagocytose tumor cells, activate the tumor micro environment (TME), recruit T cells, and present tumor antigens to T cells leading to robust anti-tumor immunity. CT-0508 is a first in class CAR-M, comprised of autologous monocyte derived ...